MedPath
HSA Approval

VASTAREL MR TABLET 35 mg

SIN12268P

VASTAREL MR TABLET 35 mg

VASTAREL MR TABLET 35 mg

April 25, 2003

SERVIER (S) PTE LTD

SERVIER (S) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantSERVIER (S) PTE LTD
Licence HolderSERVIER (S) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

**4.2 Posology and method of administration** **Posology** Oral use. The dose is one tablet of 35 mg of trimetazidine twice daily i.e. once in the morning and once in the evening during meals. The benefit of the treatment should be assessed after three months and trimetazidine should be discontinued if there is no treatment response. **Special populations** _Patients with renal impairment_ In patients with moderate renal impairment (creatinine clearance \[30–60\] ml/min) (see sections 4.4 and 5.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_), the recommended dose is 1 tablet of 35 mg in the morning during breakfast. _Elderly patients_ Elderly patients may have increased trimetazidine exposure due to age-related decrease in renal function (see section 5.2 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). In patients with moderate renal impairment (creatinine clearance \[30–60\] ml/min), the recommended dose is 1 tablet of 35 mg in the morning during breakfast. Dose titration in elderly patients should be exercised with caution (see section 4.4 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). _Paediatric population:_ The safety and efficacy of trimetazidine in children aged below 18 years have not been established. No data are available.

ORAL

Medical Information

**4.1 Therapeutic indications** Trimetazidine is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.

**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders. Severe renal impairment (creatinine clearance < 30ml/min).

Pending

xpending

Manufacturer Information

SERVIER (S) PTE LTD

LES LABORATOIRES SERVIER INDUSTRIE

Kotra Pharma (M) Sdn Bhd

Active Ingredients

TRIMETAZIDINE DIHYDROCHLORIDE

35 mg

Trimetazidine

Documents

Package Inserts

Vastarel MR Tablet 35mg PI.pdf

Approved: July 6, 2021

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

VASTAREL MR TABLET 35 mg - HSA Approval | MedPath